Common Constipation Drug Slows Kidney Disease in New Trial

By VirentaNews Staff — May 08, 2026

In a modest clinical research unit at the University of California, San Diego, patients with slowly failing kidneys swallowed a familiar capsule—lubiprostone, a drug typically prescribed to ease constipation. But in this trial, the stakes were far higher. For years, these individuals had watched their kidney function decline, inching toward dialysis, a fate that upends lives. Yet after six months on the medication, many showed something extraordinary: their kidneys were holding steady. In a world where chronic kidney disease (CKD) quietly afflicts over 850 million people globally and few treatments exist to slow its course, this unassuming pill may have stumbled upon a revolutionary backdoor—through the gut. The discovery hinges not on the kidneys themselves, but on the trillions of microbes living in the digestive tract, now emerging as silent regulators of distant organ health.

Kidney Function Preserved in Clinical Trial

In a randomized, double-blind trial of 150 adults with moderate chronic kidney disease, those who took lubiprostone twice daily for six months experienced a 40% slower decline in glomerular filtration rate (GFR), a key measure of kidney function, compared to the placebo group. The results, published in Nature Medicine, surprised even the researchers. Lubiprostone, sold under the brand name Amitiza, is an FDA-approved treatment for irritable bowel syndrome and chronic idiopathic constipation. It works by activating chloride channels in the intestines to increase fluid secretion and motility. But in this study, its impact extended far beyond bowel movements. Patients on the drug also showed reduced levels of inflammatory markers like interleukin-6 and lower levels of fibrosis in kidney tissue biopsies. Most strikingly, researchers detected a significant rise in blood levels of spermidine, a polyamine known to support mitochondrial function and cellular repair. The effect appeared strongest in those whose gut microbiomes shifted toward species known to produce spermidine precursors.

The Gut-Kidney Axis Emerges

For decades, nephrologists focused on blood pressure, glucose control, and proteinuria as the main levers for managing CKD. But recent research has illuminated a more complex picture—one in which the gut microbiome plays a pivotal role. As kidney function declines, waste products like urea accumulate in the blood and leak into the intestines, altering the gut environment. This fosters the growth of harmful bacteria that produce toxins such as indoxyl sulfate and p-cresol, which further damage kidney tissue. This creates a vicious cycle. Scientists began calling it the gut-kidney axis. Early interventions, like prebiotics or dietary fiber, showed modest promise. But the lubiprostone trial marks the first time a pharmaceutical agent has demonstrably broken this cycle by reshaping microbial metabolism. The drug appears to improve gut barrier integrity, reduce bacterial translocation, and promote the growth of beneficial microbes like Lactobacillus and Bifidobacterium, which are associated with higher spermidine production. The study’s authors suggest that lubiprostone’s chloride channel activation may create a more hospitable environment for these microbes.

The Researchers Behind the Discovery

The trial was led by Dr. Michelle Ju, a nephrologist and microbiome researcher at UC San Diego, who has long suspected that gut-targeted therapies could alter the course of kidney disease. “We’ve been treating the kidney as an isolated organ for too long,” Ju said in an interview. “But it’s in constant conversation with the gut.” Her team began exploring lubiprostone after earlier animal studies showed that mice with CKD had depleted spermidine levels and that supplementation could slow disease progression. When they analyzed stool samples from trial participants, they found that responders—those with improved kidney metrics—had a distinct microbial signature, including higher abundance of Prevotella and Faecalibacterium prausnitzii, both linked to anti-inflammatory effects. The researchers emphasize that lubiprostone isn’t a cure, but a potential disease-modifying agent. Their motivation is clear: to delay or prevent dialysis, which affects over 2 million people worldwide and carries a high burden of cost and morbidity.

Implications for Patients and Clinicians

If confirmed in larger trials, lubiprostone could become the first microbiome-targeting therapy approved for chronic kidney disease. For patients, this could mean a non-invasive, oral treatment that slows progression without the side effects of immunosuppressants or complex dietary restrictions. Given that lubiprostone has been used for over 15 years with a well-established safety profile, regulatory approval for this new indication could be expedited. However, caution remains. The current trial was small and short-term. Long-term effects on hard outcomes like dialysis initiation or mortality are unknown. Moreover, not all patients responded equally—suggesting that microbiome composition may predict treatment success. This raises the possibility of personalized approaches, where patients are screened for microbial biomarkers before starting therapy. Nephrologists may soon need to think like microbiologists, monitoring gut health as closely as blood pressure.

The Bigger Picture

This study is part of a broader scientific shift: the recognition that organ systems are deeply interconnected through biochemical signals mediated by the microbiome. Similar gut-driven mechanisms are being explored in heart failure, neurodegenerative diseases, and liver cirrhosis. The idea that a constipation drug could protect kidneys underscores the power of repurposing existing medications through a new biological lens. It also highlights the untapped therapeutic potential of microbial metabolites like spermidine, which is being studied for its anti-aging properties. As research from the European Molecular Biology Laboratory has shown, these compounds influence cellular energy, inflammation, and autophagy across tissues. The future of medicine may lie not in designing new drugs, but in understanding how old ones work in unexpected ways.

What comes next is a larger, multicenter phase 3 trial planned for 2025, involving over 1,000 CKD patients across North America and Europe. Researchers will track not only kidney function but also quality of life, hospitalizations, and microbial changes over time. If results hold, lubiprostone could redefine the standard of care. More importantly, it may open the door to a new class of ‘microbiome modulators’—drugs that don’t target organs directly, but tune the microbial ecosystem to restore systemic health. For millions facing the slow march of kidney disease, the future may depend not on a dialysis machine, but on the trillions of microbes inside them.

Source: ScienceDaily